BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 18039120)

  • 1. Spectrum of Epstein-Barr virus-associated diseases.
    Kutok JL; Wang F
    Annu Rev Pathol; 2006; 1():375-404. PubMed ID: 18039120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas.
    Kingma DW; Weiss WB; Jaffe ES; Kumar S; Frekko K; Raffeld M
    Blood; 1996 Jul; 88(1):242-51. PubMed ID: 8704180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ecology and pathology of Epstein-Barr virus.
    Schmidt CW; Misko IS
    Immunol Cell Biol; 1995 Dec; 73(6):489-504. PubMed ID: 8713470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early stage of Epstein-Barr virus lytic infection leading to the "starry sky" pattern formation in endemic Burkitt lymphoma.
    Fujita S; Buziba N; Kumatori A; Senba M; Yamaguchi A; Toriyama K
    Arch Pathol Lab Med; 2004 May; 128(5):549-52. PubMed ID: 15086279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
    Niedobitek G; Agathanggelou A; Rowe M; Jones EL; Jones DB; Turyaguma P; Oryema J; Wright DH; Young LS
    Blood; 1995 Jul; 86(2):659-65. PubMed ID: 7605996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus-associated lymphoproliferative disorders.
    Grywalska E; Markowicz J; Grabarczyk P; Pasiarski M; RoliƄski J
    Postepy Hig Med Dosw (Online); 2013 May; 67():481-90. PubMed ID: 23752600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells.
    Sugiura M; Imai S; Tokunaga M; Koizumi S; Uchizawa M; Okamoto K; Osato T
    Br J Cancer; 1996 Aug; 74(4):625-31. PubMed ID: 8761381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
    Longnecker R
    Adv Cancer Res; 2000; 79():175-200. PubMed ID: 10818681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus: 40 years on.
    Young LS; Rickinson AB
    Nat Rev Cancer; 2004 Oct; 4(10):757-68. PubMed ID: 15510157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of the latent-lytic switch in Epstein-Barr virus.
    Kenney SC; Mertz JE
    Semin Cancer Biol; 2014 Jun; 26():60-8. PubMed ID: 24457012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus.
    Rickinson A
    Virus Res; 2002 Jan; 82(1-2):109-13. PubMed ID: 11885937
    [No Abstract]   [Full Text] [Related]  

  • 13. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
    De Leo A; Arena G; Stecca C; Raciti M; Mattia E
    Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactivation of Epstein-Barr virus from latency.
    Amon W; Farrell PJ
    Rev Med Virol; 2005; 15(3):149-56. PubMed ID: 15546128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
    Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
    Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells.
    Niedobitek G; Agathanggelou A; Herbst H; Whitehead L; Wright DH; Young LS
    J Pathol; 1997 Jun; 182(2):151-9. PubMed ID: 9274524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of cell differentiation, one of the mechanisms in the surveillance of malignancy.
    Klein E; Nagy N; Rasul E
    Cancer Immunol Res; 2015 Feb; 3(2):97-102. PubMed ID: 25660552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases.
    Cohen JI
    Semin Hematol; 2003 Apr; 40(2):116-23. PubMed ID: 12704588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Epstein-Barr virus (EBV)].
    Seigneurin JM
    Rev Prat; 1999 Dec; 49(20):2217-21. PubMed ID: 10731805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of Epstein-Barr virus (EBV)-positive Hodgkin lymphoma and Hodgkin lymphoma-like B-cell lymphoproliferations with EBV latency profile 2 in children with interleukin-2-inducible T-cell kinase deficiency.
    Bienemann K; Borkhardt A; Klapper W; Oschlies I
    Histopathology; 2015 Nov; 67(5):607-16. PubMed ID: 25728094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.